Pulmonx (NASDAQ:LUNG) Stock Rating Upgraded by Wall Street Zen

Pulmonx (NASDAQ:LUNG) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Sunday.

LUNG has been the subject of several other research reports. Stifel Nicolaus lowered their target price on shares of Pulmonx from $16.00 to $5.00 and set a “buy” rating for the company in a report on Thursday, July 31st. Lake Street Capital decreased their price objective on shares of Pulmonx from $8.00 to $4.00 and set a “buy” rating for the company in a research note on Tuesday, October 28th. D. Boral Capital restated a “buy” rating and set a $14.00 target price on shares of Pulmonx in a research report on Thursday. Piper Sandler lowered Pulmonx from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $9.00 to $2.50 in a research note on Thursday, July 31st. Finally, Wells Fargo & Company cut their price objective on Pulmonx from $6.00 to $3.00 and set an “equal weight” rating on the stock in a research report on Friday, August 1st. Five analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Pulmonx presently has an average rating of “Hold” and an average price target of $6.81.

Pulmonx Price Performance

LUNG stock opened at $1.49 on Friday. Pulmonx has a 52 week low of $1.47 and a 52 week high of $9.37. The firm has a market capitalization of $61.46 million, a P/E ratio of -1.06 and a beta of 0.44. The company has a fifty day simple moving average of $1.71 and a two-hundred day simple moving average of $2.35. The company has a quick ratio of 4.63, a current ratio of 4.86 and a debt-to-equity ratio of 0.62.

Pulmonx (NASDAQ:LUNG) last announced its earnings results on Wednesday, November 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.06. The firm had revenue of $21.50 million for the quarter, compared to analysts’ expectations of $20.78 million. Pulmonx had a negative net margin of 61.91% and a negative return on equity of 77.58%. Pulmonx has set its FY 2025 guidance at EPS. Analysts anticipate that Pulmonx will post -1.55 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. ADAR1 Capital Management LLC lifted its holdings in shares of Pulmonx by 4.9% during the 3rd quarter. ADAR1 Capital Management LLC now owns 214,497 shares of the company’s stock valued at $347,000 after purchasing an additional 10,000 shares during the last quarter. Two Sigma Investments LP increased its position in Pulmonx by 50.3% during the 3rd quarter. Two Sigma Investments LP now owns 46,456 shares of the company’s stock valued at $75,000 after buying an additional 15,557 shares in the last quarter. GSA Capital Partners LLP raised its stake in Pulmonx by 78.3% in the third quarter. GSA Capital Partners LLP now owns 755,467 shares of the company’s stock valued at $1,224,000 after buying an additional 331,742 shares during the last quarter. Perkins Capital Management Inc. boosted its holdings in Pulmonx by 110.0% in the third quarter. Perkins Capital Management Inc. now owns 21,000 shares of the company’s stock worth $34,000 after acquiring an additional 11,000 shares in the last quarter. Finally, SG Americas Securities LLC boosted its holdings in Pulmonx by 95.8% in the third quarter. SG Americas Securities LLC now owns 24,863 shares of the company’s stock worth $40,000 after acquiring an additional 12,166 shares in the last quarter. 91.04% of the stock is currently owned by institutional investors.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.